Chen et al., 2022 - Google Patents
mRNA vaccines against SARS‐CoV‐2 variants delivered by lipid nanoparticles based on novel ionizable lipidsChen et al., 2022
View PDF- Document ID
- 17940399642290891356
- Author
- Chen K
- Fan N
- Huang H
- Jiang X
- Qin S
- Xiao W
- Zheng Q
- Zhang Y
- Duan X
- Qin Z
- Liu Y
- Zeng J
- Wei Y
- Song X
- Publication year
- Publication venue
- Advanced functional materials
External Links
Snippet
SARS‐CoV‐2 variants are now still challenging all the approved vaccines, including mRNA vaccines. There is an urgent need to develop new generation mRNA vaccines with more powerful efficacy and better safety against SARS‐CoV‐2 variants. In this study, a new set of …
- 229920002106 messenger RNA 0 title abstract description 134
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | mRNA vaccines against SARS‐CoV‐2 variants delivered by lipid nanoparticles based on novel ionizable lipids | |
| Gote et al. | A comprehensive review of mRNA vaccines | |
| Li et al. | A comprehensive review of the global efforts on COVID-19 vaccine development | |
| Li et al. | Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA | |
| Lutz et al. | Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines | |
| Appelberg et al. | Nucleoside-modified mRNA vaccines protect IFNAR–/–mice against Crimean-Congo hemorrhagic fever virus infection | |
| Nel et al. | Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape | |
| Nkanga et al. | Injectable slow-release hydrogel formulation of a plant virus-based COVID-19 vaccine candidate | |
| Pomatto et al. | Plant-derived extracellular vesicles as a delivery platform for RNA-based vaccine: feasibility study of an oral and intranasal SARS-CoV-2 vaccine | |
| Sartorius et al. | Arming filamentous bacteriophage, a nature-made nanoparticle, for new vaccine and immunotherapeutic strategies | |
| Andresen et al. | Nucleic acid delivery and nanoparticle design for COVID vaccines | |
| Rouf et al. | Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases | |
| Yang et al. | RBD-modified bacterial vesicles elicited potential protective immunity against SARS-CoV-2 | |
| Ross et al. | Combination nanovaccine demonstrates synergistic enhancement in efficacy against influenza | |
| Li et al. | Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys | |
| Borgoyakova et al. | Self-assembled particles combining SARS-CoV-2 RBD protein and RBD DNA vaccine induce synergistic enhancement of the humoral response in mice | |
| Rahman et al. | An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo | |
| Lim et al. | Cationic Poly (Amino Acid) Vaccine Adjuvant for Promoting Both Cell‐Mediated and Humoral Immunity Against Influenza Virus | |
| Andersen et al. | A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza | |
| Takanashi et al. | Delivery and expression of mRNA in the secondary lymphoid organs drive immune responses to lipid nanoparticle-mRNA vaccines after intramuscular injection | |
| Chen et al. | A polymer-based antigen carrier activates two innate immune pathways for adjuvant-free subunit vaccines | |
| Cheng et al. | A synergistic lipid nanoparticle encapsulating mRNA shingles vaccine induces potent immune responses and protects Guinea pigs from viral challenges | |
| Cui et al. | Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza | |
| Firdaus et al. | Liposomal formulations of a polyleucine–antigen conjugate as therapeutic vaccines against cervical cancer | |
| Files et al. | Self-adjuvanting nanovaccines boost lung-resident CD4+ T cell immune responses in BCG-primed mice |